Bexion Pharma has received the Phase II SBIR grant to identify and select optimised SapC-DOPS formulations and treatment methods for glioblastoma multiforme, suitable for advancing Bexion’s drug toward planned human testing.
NCI has previously selected Bexion for a notable research collaboration with its Nanotechnology Characterisation Laboratory (NCL), a part of a major program, the Alliance for Nanotechnology in Cancer, to advance the medical applications of nanotechnology.
Bexion claimed that its proprietary technology is based on Saposin C- dioleoylphosphatidylserine (dubbed ‘SapC-DOPS’) and is a nanovesicle therapeutic for the treatment of glioblastomas (GBM), pancreatic cancers and other solid tumors.
Bexion co-founder and CEO Ray Takigiku said that the Phase II award will expedite their goal to develop a new molecular entity with a new mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma).